ADvantage Therapeutics (ADTx) is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s Disease (AD). The Company’s lead compound AD04™ is a subcutaneous injectable therapy that has entered confirmatory Phase 2b clinical trials in Europe, to evaluate its safety and efficacy in early AD patients. The Company believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, indirectly triggering the elimination of misfolded proteins, beta amyloid and tau. Based in Miami with a research subsidiary in Vienna, the Company conducts early research and drug development to explore additional approaches to mitigating neurodegenerative disease, among them increasing the levels of Klotho, a life and health extending protein with an overall impact on longevity.